Report on clinical progress and published trial results for an oral therapy targeting lower-risk myelodysplastic syndromes and next development steps.
Key Takeaways
- FDA granted Fast Track designation to ofirnoflast (HT-6184) for lower-risk MDS
- Phase 2 single-arm trial enrolled 37 adults and tested the oral regimen
- Among 30 evaluable patients the overall hematologic improvement rate was 67%